Aidoc Raises $150M Series E Led by Goldman Sachs — Clinical-AI Foundation Model CARE Eyes IPO Within 5 Years (April 29, 2026)

Clinical-AI vendor Aidoc on April 29, 2026 closed a $150 million Series E led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Vision Fund 2, and NVentures — Nvidia's venture arm. The round pushes Aidoc's total funding past $520 million and sets the company up for a planned IPO inside the next three to five years.

What Happened

Aidoc's Series E follows a growth round led by General Catalyst and Square Peg less than a year earlier. The new capital is earmarked for the company's clinical foundation model, CARE, and the surrounding enterprise platform, aiOS. Founder and CEO Elad Walach told Axios the company already runs across roughly 2,000 hospitals and analyzes more than 60 million patient cases a year, and that the round positions Aidoc to be "IPO-ready in three to five years."

Earlier in 2026, CARE secured what Aidoc calls the first FDA clearance for a comprehensive foundation-model-based triage system in clinical imaging — the company now holds 31 FDA clearances spanning emergency-department workflows, stroke detection, pulmonary embolism triage, and abdominal scan reads.

Key Details

• Round size: $150 million Series E, valuation undisclosed.
• Lead investor: Growth Equity at Goldman Sachs Alternatives.
• Participants: General Catalyst, SoftBank Vision Fund 2, NVentures (Nvidia).
• Total raised to date: $520 million across previous Series A through D rounds.
• Use of funds: Expanding the CARE foundation model, building automated imaging draft-report features, and broader global deployment of aiOS.
• Regulatory footprint: 31 FDA clearances; CARE holds the first clearance for a comprehensive foundation-model-based triage system, per the company's release.
• Stated IPO horizon: 3 to 5 years.

What Developers and Users Are Saying

Reaction across health-tech Twitter and LinkedIn was largely positive but pointed. Investors and analysts framed the round as part of a broader shift in healthcare AI: capital is flowing to vendors that have already cleared FDA review and demonstrated production deployments, not to teams shipping new models in isolation. MobiHealthNews called the deal a sign that hospitals are consolidating point-solution AI tools under platform vendors. On Hacker News, several radiologists in the comments echoed a familiar concern — that triage AI is now ubiquitous in large US health systems but remains a hard sell to smaller community hospitals because of integration cost and EMR friction.

Critics on r/Radiology questioned whether a single foundation model can really cover the breadth of imaging modalities Aidoc claims, and called for more peer-reviewed outcome data alongside the FDA clearances. Supportive voices pointed to the company's published analysis volume — 60 million cases per year — as evidence the platform is at least live in real workflows, not stuck in pilots.

What This Means for Developers and Health Systems

For clinical AI builders, the round is a signal that the funding bar in healthcare is now regulatory traction plus measurable outcomes, not benchmark scores. Series E money at this scale is unusual for clinical AI without a clear FDA story. For hospital IT teams, expect Aidoc to push harder on aiOS as a single integration point that replaces multiple narrow-AI vendors. The new automated draft-report feature, in particular, lands in the same workflow space as Microsoft's Nuance DAX and a wave of generative-radiology startups.

What's Next

Aidoc said the capital will fund continued CARE training, new clinical indications, and additional regulatory submissions in the US and abroad. Walach told Axios the company is profitable on a unit-economics basis in mature markets and that the IPO timeline depends on "public-market conditions for healthcare AI." Watch for further FDA clearances and an aiOS partner ecosystem expansion in the second half of 2026.

Sources

• Aidoc — Series E announcement (primary source)
• Axios — Exclusive on the round and IPO timeline
• Goldman Sachs Asset Management — Investor release
• MobiHealthNews — Industry analysis
• Radiology Business — Radiology-vendor angle
• Aidoc blog — "The End of the Beginning"